Feature

Video

Sponsored

Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials

Author(s):

Lightship

Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research organization (CRO) partners to support clinical trials that are patient-first and accessible.

Lightship prioritizes patient accessibility and centricity in clinical trials, ensuring a seamless and positive experience for every participant. Learn more about:

  • Lightship's mission and core purpose as a company
  • How Lightship’s mobile nursing teams and home visits enhance study participation and retention
  • The role of mobile research units in the community and how they enhance participant education, accessibility, and convenience

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
August 4th 2025

2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research

Don Tracy, Associate Editor
Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
2025 DIA Global Annual Meeting: The Truth About AI Adoption Speed in Clinical Research
August 4th 2025

2025 DIA Global Annual Meeting: The Truth About AI Adoption Speed in Clinical Research

Don Tracy, Associate Editor
Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.
2025 DIA Global Annual Meeting: The Adoption of Artificial Intelligence and Machine Learning in Clinical Research
August 4th 2025

2025 DIA Global Annual Meeting: The Adoption of Artificial Intelligence and Machine Learning in Clinical Research

Andy Studna, Senior Editor
Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.
2025 DIA Global Annual Meeting Opening Keynote Panel: Global Collaboration to Derisk Innovation and Improve Patient Lives
August 4th 2025

2025 DIA Global Annual Meeting Opening Keynote Panel: Global Collaboration to Derisk Innovation and Improve Patient Lives

Andy Studna, Senior Editor
Global R&D leaders discuss the need for collaboration in medical research and how regulatory agencies are working to create the proper environment for advancements.
Credit: Crystal light | stock.adobe.com. Stomach cancer, gastric cancer, symptoms, stages, treatment, 3d illustration
August 4th 2025

Phase III MATTERHORN Trial Shows Imfinzi Combo Significantly Improves Event-Free Survival in Resectable Gastric and GEJ Cancers

Davy James
Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically significant event-free survival in a Phase III trial for resectable gastric and gastroesophageal junction cancers, signaling a potential shift in standard perioperative care.
© iDoPixBox - © iDoPixBox - stock.adobe.com
August 4th 2025

Tecentriq and Zepzelca Combo Demonstrates Significant Survival Benefit in Phase III Study for Extensive-Stage Small Cell Lung Cancer

Andy Studna, Senior Editor
In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression or death by 46% as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
© 2025 MJH Life Sciences

All rights reserved.